Preliminary program outline

Wednesday	September 25
09.00-10.00	Registration
	Opening Session
10.15-10.20	Welcome (TBD)
10.20-10.50	Opening Plenary (Pl1) The Russian HIV epidemic (Vadim Pokrovskiy, Russia)
10.50-11.00	Discussion
	Abstract Session I
11.00-11.15	Oral 1 (10 min + 5 min discussion)
11.15-11.30	Oral 2
11.30-11.45	Oral 3
11.45-12.00	Oral 4
12.00-13.00	Lunch
13.00-13.50	BHIVA and HIV Nordic joint session – Evolving HIV treatment and care
	New drugs and treatment strategies (Chloe Orkin, UK)
	Cervical cancer and dysplasia in HIV (Christina Carlander, Sweden)
	Discussion
	Plenary session I – HIV treatment and clinical challenges
13.50-14.15	Plenary (Pl2) INSTI adverse events – what is the truth? (Jan Gerstoft, Denmark)
14.15-14.25	Discussion
14.25-14.40	Short Break
14.40-15.10	Plenary (Pl3) Update on ART and birth defects (Lynne M Mofenson, USA)
15.10-15.20	Discussion
15.20-15.50	Plenary (Pl4) Resurgent STIs in HIV Care and Prevention (Sharon Walmsley, Canada)
15.50-16.00	Discussion
16.00-16.30	Coffee and exhibition/posters
16.30-17.30	Satellite Symposium 1 – MSD
17.30-17.45	Short break
17.45-18.45	Satellite Symposium 2 – Gilead HIV
18.45-	Poster Exhibition with cheese and snacks

Thursday	September 26
08.00-09.00	Satellite Symposium 3 – GSK/ViiV
09.00-09.10	Short break
	Plenary Session II – Reservoirs and Cure
09.10-09.40	Plenary (Pl5) New insights in formation of the HIV reservoir (Ron Swanstrom, USA)
09.40-09.50	Discussion
09.50-10.20	Plenary (Pl6) Viral reservoirs in tissue (Jacob Estes, USA)
10.20-10.30	Discussion
10.30-11.00	Coffee and Poster exhibition
11.00-11.30	Plenary (Pl7) Functional Cure of HIV (Lucy Dorrell, Oxford, UK)
11.30-11.40	Discussion
	Plenary Session III – HIV control
11.40-12.10	Plenary (Pl8) Mechanisms of elite control (Beatriz Mothe, Spain)
12.10-12.20	Discussion
12.20-12.50	Plenary (Pl9) Mechanisms of post-treatment control (John Frater, UK)
12.50-13.00	Discussion
13.00-14.00	Lunch
	Plenary Session IV – Last year’s most important achievements in the HIV research field
14.00-14.30	Plenary (Pl10) Top 5 in basic HIV research 2018-2019 (Marianne Jansson, Sweden)
14.30-15.00	Plenary (Pl11) Top 5 in clinical HIV research 2018-2019 (Terese Katzenstein, Denmark)
	Plenary Session V – TBD
15.00-15.20	Plenary (Pl12) Update on INSTI resistance (Anne-Geneviève Marcelin, France)
15.20-15.30	Discussion
15.30-15.50	Plenary (Pl13) Significance of low-level viremia during antiretroviral treatment (Anders Sönnerborg, Sweden)
15.50-16.00	Discussion
16.00-16.20	Coffee and Poster exhibition
16.20-16.30	HIV & Hepatitis Nordic Conference 2019 Abstract Award (TBD)
16.30-17.30	Satellite Symposium 4 – Gilead Hepatitis
17.30-17.45	Short break
17.45-18.45	Satellite Symposium 5 – TBD
	Conference Dinner

Friday	September 27
08.00-09.00	Satellite Symposium 6 – TBD
	Plenary Session VI – Last year’s most important achievements in the hepatitis field
09.00-09.30	Plenary (Pl14) Top 5 in hepatitis research 2017/18 (Ola Weiland, Sweden)
09.30-09.40	Discussion
	Abstract Session II
09.40-09.55	Oral 5 (10 + 5 min discussion)
09.55-10.10	Oral 6
10.10-10.45	Coffee and Poster exhibition
	Session VII – HCV treatment among people who inject drugs - experiences from Norway, Denmark and Sweden (Martin Kåberg, Sweden & Marianne Alanko, Sweden)
10.45-12.15	Olav Dalgard (Norway) Anne Øvrehus (Denmark) Anna Jerkeman (Sweden)
12.15-13.15	Lunch
	Plenary Session VIII – Hepatitis B/D
13.15-13.35	Plenary 15 Immunological aspects of stopping NUC treatment in HBV (Niklas Björkström, Sweden)
13.35-13.45	Discussion
13.45-14.05	Plenary 16 Future options for treatment of hepatitis delta (Maria Buti, Spain)
14.05-14.15	Discussion
14.15-14.35	Plenary 17 Hepatitis B cure – progress, obstacles and definitions (TBD)
14.35-14.45	Discussion
14.45-15.00	Short break
	Plenary Session IX – Hepatitis C
15.00-15.20	Plenary 18 Aspects on HCV vaccine development (Jannick Prentø, Denmark)
15.20-15.30	Discussion
15.30-15.50	Plenary 19 Eradicating HCV, a global perspective (John Dillon, UK)
15.50-16.00	Discussion
16.00-16.15	Concluding remarks